EXTENDED REPORT

Therapeutic effect of cortistatin on experimental arthritis by downregulating inflammatory and Th1 responses

Elena Gonzalez-Rey², Alejo Chorny¹, Raimundo G Del Moral³, Nieves Varela¹, Mario Delgado¹

¹ Institute of Parasitology and Biomedicine, CSIC, Granada, Spain
² Department of Biochemistry and Molecular Biology, Medical School of Seville, Seville, Spain
³ Department of Pathology, University of Granada, Granada, Spain

Correspondence to:
Dr M Delgado
Instituto de Parasitologia y Biomedicina, CSIC, Avd. Conocimiento, PT Ciencias de la Salud, Granada 18100, Spain; mdelgado{at}ipb.csic.es

Background: Rheumatoid arthritis is a chronic autoimmune disease of unknown aetiology characterised by chronic inflammation in the joints and subsequent destruction of the cartilage and bone.

Aim: To propose a new strategy for the treatment of arthritis based on the administration of cortistatin, a newly discovered neuropeptide with anti-inflammatory actions.

Methods: DBA/1J mice with collagen-induced arthritis were treated with cortistatin after the onset of disease, and the clinical score and joint histopathology were evaluated. Inflammatory response was determined by measuring the levels of various inflammatory mediators (cytokines and chemokines) in joints and serum. T helper cell type 1 (Th1)-mediated autoreactive response was evaluated by determining the proliferative response and cytokine profile of draining lymph node cells stimulated with collagen and by assaying the content of serum autoantibodies.

Results: Cortistatin treatment significantly reduced the severity of established collagen-induced arthritis, completely abrogating joint swelling and destruction of cartilage and bone. The therapeutic effect of cortistatin was associated with a striking reduction in the two deleterious components of the disease—that is, the Th1-driven autoimmune and inflammatory responses. Cortistatin downregulated the production of various inflammatory cytokines and chemokines, decreased the antigen-specific Th1-cell expansion, and induced the production of regulatory cytokines, such as interleukin 10 and transforming growth factor ß1. Cortistatin exerted its effects on synovial cells through both somatostatin and ghrelin receptors, showing a higher effect than both peptides protecting against experimental arthritis.

Conclusion: This work provides a powerful rationale for the assessment of the efficacy of cortistatin as a novel therapeutic approach to the treatment of rheumatoid arthritis.

Abbreviations: CFA, complete Freund’s adjuvant; CIA, collagen-induced arthritis; CII, collagen type II; CST, cortistatin; DLN, draining lymph nodes; IFN, interferon; IL, interleukin; PPD, purified protein derivative; RA, rheumatoid arthritis; sst, somatostatin receptors; Th1, T helper cell type 1; TGF, transforming growth factor; TNF, tumour necrosis factor

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Duran-Prado, M., Gahete, M. D., Martinez-Fuentes, A. J., Luque, R. M., Quintero, A., Webb, S. M., Benito-Lopez, P., Leal, A., Schulz, S., Gracia-Navarro, F., Malagon, M. M., Castano, J. P. (2009). Identification and Characterization of Two Novel Truncated but Functional Isoforms of the Somatostatin Receptor Subtype 5 Differentially Present in Pituitary Tumors. J. Clin. Endocrinol. Metab. 94: 2634-2643 [Abstract] [Full Text]